{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T15:02:52Z","timestamp":1743865372420},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T00:00:00Z","timestamp":1362009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Lipoprotein glomerulopathy (LPG) is a rare inherited renal disease characterized by intraglomerular lipoprotein within the lumina of severely dilated glomerular capillaries. The common clinical presentation of LPG includes proteinuria or nephrotic syndrome. Hypertension and anemia were thought to be mild in LPG. Thrombotic microangiopathy (TMA) in LPG has not been previously reported. In this report, we present a patient with LPG that developed TMA. To the best of our knowledge, this is the first report of TMA in LPG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>Four years ago (2005), a 19-year-old Chinese woman was diagnosed with nephrotic syndrome and provided prednisone treatment. A combination of prednisone and cyclophosphamide did not have any effect and was discontinued after six months. Although she was steroid-resistant, over the next subsequent three years, she maintained normal renal function without anemia and thrombocytopenia. In February 2009, she had a severe headache and blurry vision and presented at a local hospital with severe hypertension. Blood pressure was 220\/160\u2009mmHg. Laboratory data showed hemoglobin 3.8\u2009g\/dL; platelet counts 29\u00d710<jats:sup>9<\/jats:sup>\/L; urinary protein 7.90\u2009g\/d; total bilirubin 29.9 umol\/L; indirect bilirubin 28.2 umol\/L; LDH 1172 U\/L; ALB 2.66\u2009g\/dL; urea nitrogen 52\u2009mg\/dL; serum creatinine 3.2\u2009mg\/dL; triglyceride 253\u2009mg\/dL; total cholesterol 273\u2009mg\/dL. ANA, ds-DNA, ANCA, anti-GBM antibody and anticardiolipin were all negative. A renal biopsy revealed LPG with TMA. Genetic evaluation showed the patient carried the <jats:italic>APOE<\/jats:italic> Kyoto mutation. Adequate control of blood pressure improved microangiopathic anemia and thrombocytopenia, however, renal function did not improve and she eventually developed uremia and became hemodialysis dependent.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We report on a rare case of TMA probably due to malignant hypertension in LPG. Early lipid-lowering and antihypertensive treatment may improve outcome. The pathophysiologic relationship between LPG and TMA should be investigated further.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2369-14-53","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T10:06:32Z","timestamp":1362132392000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension"],"prefix":"10.1186","volume":"14","author":[{"given":"Yu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baohe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangxue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"issue":"2","key":"469_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1053\/j.ajkd.2003.10.013","volume":"43","author":"E Liberopoulos","year":"2004","unstructured":"Liberopoulos E, Siamopoulos K, Elisaf M: Apolipoprotein E and renal disease. Am J Kidney Dis. 2004, 43 (2): 223-233. 10.1053\/j.ajkd.2003.10.013.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"469_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1050-1738(01)00148-7","volume":"12","author":"T Saito","year":"2002","unstructured":"Saito T, Ishigaki Y, Oikawa S, Yamamoto TT: Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc Med. 2002, 12 (2): 67-70. 10.1016\/S1050-1738(01)00148-7.","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"469_CR3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-2275(20)43176-1","volume":"31","author":"JE Hixson","year":"1990","unstructured":"Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990, 31 (3): 545-548.","journal-title":"J Lipid Res"},{"issue":"2","key":"469_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0272-6386(89)80134-9","volume":"13","author":"T Saito","year":"1989","unstructured":"Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y, Yoshinaga K, Sakaguchi H: Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989, 13 (2): 148-153.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"469_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2005.10.017","volume":"47","author":"T Saito","year":"2006","unstructured":"Saito T, Matsunaga A, Oikawa S: Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006, 47 (2): 199-211. 10.1053\/j.ajkd.2005.10.017.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"469_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.ajkd.2005.12.031","volume":"47","author":"R Sam","year":"2006","unstructured":"Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK: Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis. 2006, 47 (3): 539-548. 10.1053\/j.ajkd.2005.12.031.","journal-title":"Am J Kidney Dis"},{"key":"469_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/B978-0-323-05876-6.00028-9","volume-title":"Comprehensive clinical nephrology","author":"P Ruggenenti","year":"2010","unstructured":"Ruggenenti P, Cravedi P, Remuzzi G: Thrombotic microangiopathies, including hemolytic uremic syndrome. Comprehensive clinical nephrology. Edited by: Floege J, Johnson RJ, Feehally J. 2010, Missouri: Elsevier Saunders, 344-355. 4","edition":"4"},{"issue":"4","key":"469_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/jcp.2010.075739","volume":"63","author":"T Yokomine","year":"2010","unstructured":"Yokomine T, Hirakawa H, Ozawa E, Shibata K, Nakayama T: Pulmonary thrombotic microangiopathy caused by gastric carcinoma. J Clin Pathol. 2010, 63 (4): 367-369. 10.1136\/jcp.2010.075739.","journal-title":"J Clin Pathol"},{"issue":"1","key":"469_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1440-1827.2010.02608.x","volume":"61","author":"A Mii","year":"2011","unstructured":"Mii A, Shimizu A, Masuda Y, Fujino T, Kaneko T, Utsumi K, Arai T, Ishikawa A, Wakamatsu K, Tajika K, et al: Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation. Path Int. 2011, 61 (1): 34-41. 10.1111\/j.1440-1827.2010.02608.x.","journal-title":"Path Int"},{"issue":"14","key":"469_CR10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1177\/0961203310376523","volume":"19","author":"WX Hu","year":"2010","unstructured":"Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH: Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus. 2010, 19 (14): 1591-1598. 10.1177\/0961203310376523.","journal-title":"Lupus"},{"issue":"2","key":"469_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1526-0968.2003.00127.x","volume":"8","author":"JS Dlott","year":"2004","unstructured":"Dlott JS, Danielson CFM, Blue-Hnidy DE, McCarthy LJ: Drug-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004, 8 (2): 102-111. 10.1111\/j.1526-0968.2003.00127.x.","journal-title":"Ther Apher Dial"},{"issue":"11","key":"469_CR12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009","volume":"129","author":"JN George","year":"1998","unstructured":"George JN, Raskob GE, Shah SR, Rizvi M, Hamilton S, Osborne S, Vondracek T: Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998, 129 (11): 886-890.","journal-title":"Ann Intern Med"},{"issue":"1","key":"469_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","volume":"101","author":"AM Jackson","year":"1984","unstructured":"Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG: Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med. 1984, 101 (1): 41-44.","journal-title":"Ann Intern Med"},{"issue":"2","key":"469_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/10641963.2010.503303","volume":"33","author":"T Akimoto","year":"2011","unstructured":"Akimoto T, Muto S, Ito C, Takahashi H, Takeda S, Ando Y, Kusano E: Clinical features of malignant hypertension with thrombotic microangiopathy. Clin Exp Hypertens. 2011, 33 (2): 77-83. 10.3109\/10641963.2010.503303.","journal-title":"Clin Exp Hypertens"},{"issue":"5","key":"469_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/ajcp\/45.5.605","volume":"45","author":"V Pardo","year":"1966","unstructured":"Pardo V, Aburano A: Thrombotic microangiopathy and malignant hypertension. Am J Clin Pathol. 1966, 45 (5): 605-613.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"469_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","volume":"45","author":"BJ van den Born","year":"2005","unstructured":"van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA: Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005, 45 (2): 246-251. 10.1161\/01.HYP.0000151620.17905.ee.","journal-title":"Hypertension"},{"issue":"4","key":"469_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/HYPERTENSIONAHA.107.103127","volume":"51","author":"BJ van den Born","year":"2008","unstructured":"van den Born BJ, van der Hoeven NV, Groot E, Lenting PJ, Meijers JC, Levi M, van Montfrans GA: Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension. 2008, 51 (4): 862-866. 10.1161\/HYPERTENSIONAHA.107.103127.","journal-title":"Hypertension"},{"issue":"1","key":"469_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1291\/hypres.28.89","volume":"28","author":"Y Shibagaki","year":"2005","unstructured":"Shibagaki Y, Fujita T: Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)\/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?. Hypertens Res. 2005, 28 (1): 89-95. 10.1291\/hypres.28.89.","journal-title":"Hypertens Res"},{"issue":"8","key":"469_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/00004872-199508000-00013","volume":"13","author":"GY Lip","year":"1995","unstructured":"Lip GY, Beevers M, Beevers DG: Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens. 1995, 13 (8): 915-924. 10.1097\/00004872-199508000-00013.","journal-title":"J Hypertens"},{"issue":"3","key":"469_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ndt\/gfn555","volume":"24","author":"Z Xin","year":"2009","unstructured":"Xin Z, Zhihong L, Shijun L, Jinfeng Z, Huiping C, Caihong Z, Daxi J, Leishi L: Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Nephrol Dial Transplant. 2009, 24 (3): 864-869.","journal-title":"Nephrol Dial Transplant"},{"key":"469_CR21","doi-asserted-by":"publisher","first-page":"9311","DOI":"10.1186\/1752-1947-3-9311","volume":"3","author":"G Russi","year":"2009","unstructured":"Russi G, Furci L, Leonelli M, Magistroni R, Romano N, Rivasi P, Albertazzi A: Lipoprotein glomerulopathy treated with LDL-apheresis (heparin-induced extracorporeal lipoprotein precipitation system): a case report. J Med Case Reports. 2009, 3: 9311-10.1186\/1752-1947-3-9311.","journal-title":"J Med Case Reports"},{"issue":"6","key":"469_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10157-010-0333-9","volume":"14","author":"H Hamatani","year":"2010","unstructured":"Hamatani H, Hiromura K, Kobatake K, Yoshida H, Kobayashi S, Yoneda N, Kayakabe K, Matsumoto T, Kuroiwa T, Ueki K, et al: Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol. Clin Exp Nephrol. 2010, 14 (6): 619-624. 10.1007\/s10157-010-0333-9.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"469_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10157-009-0207-1","volume":"13","author":"A Matsunaga","year":"2009","unstructured":"Matsunaga A, Furuyama M, Hashimoto T, Toyoda K, Ogino D, Hayasaka K: Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol. 2009, 13 (6): 659-662. 10.1007\/s10157-009-0207-1.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"469_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/ajkd.2003.50016","volume":"41","author":"N Ieiri","year":"2003","unstructured":"Ieiri N, Hotta O, Taguma Y: Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis. 2003, 41 (1): 244-249. 10.1053\/ajkd.2003.50016.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"469_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0021-9150(03)00194-1","volume":"169","author":"T Arai","year":"2003","unstructured":"Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K, Kanayama Y, Himeno S, Matsuzawa Y: Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis. 2003, 169 (2): 293-299. 10.1016\/S0021-9150(03)00194-1.","journal-title":"Atherosclerosis"},{"issue":"1","key":"469_CR26","first-page":"193","volume":"18","author":"DC Fisher","year":"1996","unstructured":"Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M, Ross M, Petros W, Peters WP: Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transplant. 1996, 18 (1): 193-198.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"469_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4065\/74.6.570","volume":"74","author":"C Porta","year":"1999","unstructured":"Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E: Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc. 1999, 74 (6): 570-574. 10.4065\/74.6.570.","journal-title":"Mayo Clin Proc"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-14-53\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-53","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:25:18Z","timestamp":1630535118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-14-53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-14-53","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,28]]},"assertion":[{"value":"8 September 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"53"}}